Accelerate to discover
Related topics
EV's and Nanoparticles in "Full Spectrum View" with the new Cytek ESP module
Jul 19, 2024
Cytek’s Enhanced Small Particle (ESP) Detection Option expands the capability of your Cytek Aurora or Cytek Northern...
Automatic, Real Time Acquisition of Bioluminescent Kinetic Curves
Jun 27, 2024
Watch this pre-recorded webinar with Dr. Andrew Van Praagh to learn how our new Aura software feature —Kinetics—...
Theranostics: From Mice to Men and Back
Jun 25, 2024
Recorded webinar
Presenters: Prof. Dr. Ken Herrmann and Prof. Dr. Katharina Lückerath – Moderator: Hannah Notebaert
Orion 2024 AACR poster: 17-plex single-step stain and imaging of cell Lung Carcinoma
Jun 21, 2024
RareCyte Orion is a benchtop, high resolution, whole slide multimodal imaging instrument. A combination of quantitative...
New release now available: Cytek Amnis AI v3.0 Software
Jun 17, 2024
The new Cytek Amnis AI v3.0 image analysis software features an integrated transfer learning algorithm, an option to...
Cytek webinar: Imaging Flow Cytometry for Chromosomal Assessment in Hematological Malignancies
Jun 7, 2024
In this webinar, we will describe a new innovative approach we developed that resolves these limitations. The method...
X-RAD 320 for irradiation therapy during quantifying study for in vivo collagen reorganization
Jun 5, 2024
Quantifying in vivo collagen reorganization during immunotherapy in murine melanoma with second harmonic generation...
Use of MRI and microCT to evaluate gene therapy for the treatment of discogenic back pain
Jun 4, 2024
MRI images were obtained using the 9.4T Bruker BioSpec system, equipped with 40 mm 1H quadrature volume resonator, and...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Related technologies: HTP Screening
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
